<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04766307</url>
  </required_header>
  <id_info>
    <org_study_id>2015ZX10003001-002</org_study_id>
    <nct_id>NCT04766307</nct_id>
  </id_info>
  <brief_title>A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2</brief_title>
  <official_title>A Randomized Multicenter Clinical Trial of a New Treatment for Primary Smear- Positive Pulmonary Tuberculosis With Interleukin-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chest Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the efficacy and safety of standard chemotherapy&#xD;
      regimen 2HRZE/4HR plus IL-2 and standard regimen 2HRZE/4HR for newly diagnosed smear positive&#xD;
      pulmonary tuberculosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Design:The study is a multi-center, randomized, controlled, open clinical trial.&#xD;
&#xD;
        2. Population:Initial smear positive pulmonary tuberculosis patients who fulfill the&#xD;
           inclusion and exclusion criteria.&#xD;
&#xD;
        3. Investigational regimens:&#xD;
&#xD;
           Experimental group regimen:2HRZE/4HR+Interleukin-2 （500000 units daily, subcutaneous&#xD;
           injection in the first month） The control group regimen: 2HRZE/4HR Dosage: isoniazid&#xD;
           300mg(given once daily),rifampin 450mg(less than 50kg,given once daily) or 600mg(more&#xD;
           than 50kg,given once daily),pyrazinamide 1500mg(less than 50kg,given once daily) or&#xD;
           30mg/kg(more than 50kg,given once daily),ethambutol 750mg(less than 50kg,given once&#xD;
           daily) or 1000mg(more than 50kg,given once daily).&#xD;
&#xD;
        4. Primary and Secondary outcome measures:&#xD;
&#xD;
      primary efficacy outcome measures:(a)Negative conversion rate of sputum bacteria. (b)Sputum&#xD;
      smear conversion proportion at the treatment completion .&#xD;
&#xD;
      secondary efficacy outcome measure:Recurrence rate after treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary study endpoint was the proportion of subjects who had converted their sputum cultures to negative at the end of treatment.</measure>
    <time_frame>two-month course intensive phase treatment, followed by a four-month consolidation phase treatment.Some TB patients with cavity should receive 9 total months (7 months of continuation therapy after the initial 2-month intensive phase).</time_frame>
    <description>A cure was defined as who was smear- or culture-negative in the last month of treatment and on at least one previous occasion. Treatment completion was defined as patients who completed treatment but who does not have a negative sputum smear or culture result in the last month of treatment and on at least one previous occasion. Treatment failure was defined as patients whose sputum smear or culture is positive at 5 months or later during treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Tuberculosis, Pulmonary</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group regimen:2H(Isoniazid)R(Rifampicin)Z(Pyrazinamide)E(Ethambutol)/4HR+Interleukin-2 （500000 units daily, subcutaneous injection in the first month）&#xD;
Dosage: isoniazid 300mg(given once daily),rifampin 450mg(less than 50kg,given once daily) or 600mg(more than 50kg,given once daily),pyrazinamide 1500mg(less than 50kg,given once daily) or 30mg/kg(more than 50kg,given once daily),ethambutol 750mg(less than 50kg,given once daily) or 1000mg(more than 50kg,given once daily).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control regimen group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group regimen: 2H(Isoniazid)R(Rifampicin)Z(Pyrazinamide)E(Ethambutol)/4HR&#xD;
Dosage: isoniazid 300mg(given once daily),rifampin 450mg(less than 50kg,given once daily) or 600mg(more than 50kg,given once daily),pyrazinamide 1500mg(less than 50kg,given once daily) or 30mg/kg(more than 50kg,given once daily),ethambutol 750mg(less than 50kg,given once daily) or 1000mg(more than 50kg,given once daily).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-2</intervention_name>
    <description>Interleukin 2 (IL-2) is a pleiotropic cytokine that is produced after antigen activation and plays crucial roles in the immune response. IL-2 secreted by activated T cells is central to the development of an immune response to infection, promoting the differentiation and proliferation of lymphoid cells. This hydrophobic molecule and the various cytokines that it elicits regulates the behavior of T and B lymphocytes, monocytes/macrophages, natural killer (NK) cells, and neutrophils. IL-2 therapy regimens are expected to limit mycobacterial replication. Early clinical trials with IL-2 demonstrated that IL-2 immunotherapy may be useful in controlling infectious disease.</description>
    <arm_group_label>Control regimen group</arm_group_label>
    <arm_group_label>experimental group</arm_group_label>
    <other_name>IL-2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Is willing and able to give informed consent to participate in the trial treatment and&#xD;
             follow-up (signed or witnessed consent if the patient is illiterate).&#xD;
&#xD;
          2. Is aged 18-65 years.&#xD;
&#xD;
          3. Chest X-ray showed that there were active tuberculosis foci in the lungs with one of&#xD;
             the following cases: (1) sputum specimens (or sputum and bronchial lavage fluid) were&#xD;
             2+ once or 1+ twice ; (2) sputum smear positive and sputum X-pert positive.&#xD;
&#xD;
          4. Newly diagnosed cases receiving anti-TB treatment for less than one month.&#xD;
&#xD;
          5. No other immune preparations （such as: thymosin，IFN-y，BCG-PSN，Mycobacterium&#xD;
             vaccae，Utilins，lentinan ）were used in the past 3 months.&#xD;
&#xD;
          6. the urine analysis of Women of childbearing age are negative and agree to use the&#xD;
             efficient contraception during the study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has a known allergy to any drug of treatment regimens.&#xD;
&#xD;
          2. There are serious complications or impaired renal function (serum creatinine is 1.5&#xD;
             times higher than the normal limit) or impaired liver function (ALT or AST levels are&#xD;
             3 times higher than the normal limit); hemoglobin is less than 7.0g/dl. Platelets less&#xD;
             than 50x109/L.&#xD;
&#xD;
          3. Complication with Diabetic.&#xD;
&#xD;
          4. The screening diagnosis was isoniazid resistance or rifampin resistance&#xD;
&#xD;
          5. There are serious cardiovascular diseases, such as heart failure, hypertension,&#xD;
             arrhythmia or post myocardial infarction state.&#xD;
&#xD;
          6. Is known to be pregnant or breast-feeding.&#xD;
&#xD;
          7. Karnofsky score is less than 50%.&#xD;
&#xD;
          8. Is taking any clinical trial in the past 3 months.&#xD;
&#xD;
          9. Is critically ill, and in the judgment of the investigator, not fit for the study or&#xD;
             unlikely to complete the full course of study.&#xD;
&#xD;
         10. HIV is positive or AIDS patients.&#xD;
&#xD;
         11. Has Non tuberculous mycobacterial lung disease.&#xD;
&#xD;
         12. Merge with extra pulmonary tuberculosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naihui Chu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chest Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Naihui Chu, PhD</last_name>
    <email>dongchu1994@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>the Second hospital of Fuyang</name>
      <address>
        <city>Fuyang</city>
        <state>Anhui</state>
        <zip>230000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>haiqing Liu</last_name>
      <phone>13855894607</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fuzhou Chest Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xiaohong Chen</last_name>
      <phone>13275013012</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen third people's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangzhou</state>
        <zip>518000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>qunyi Deng</last_name>
      <phone>13823145706</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guiyang Public Health Treatment Center</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jing Chen</last_name>
      <phone>13985410691</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Infectious Hospital of Handan</name>
      <address>
        <city>Handan</city>
        <state>Hebei</state>
        <zip>056000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>chunyan Zhang</last_name>
      <phone>15803200615</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hebei Chest Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhihui Li</last_name>
      <phone>13833465658</phone>
      <email>lzhihui2011@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiamusi Insititute For Tuberculosis Control</name>
      <address>
        <city>Jiamusi</city>
        <state>Heilongjiang</state>
        <zip>154000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>chao Qiu</last_name>
      <phone>13039651567</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Infectious Hospital of mudanjiang</name>
      <address>
        <city>Mudanjiang</city>
        <state>Heilongjiang</state>
        <zip>150000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lixiang Chu</last_name>
      <phone>18645753107</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhengzhou Sixth People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yu Chen</last_name>
      <phone>13823145706</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>the central hospital of Changsha</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>chunxiang Li</last_name>
      <phone>13055161267</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>the people's hospital of Jiangsu province</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hong Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangxi Chest Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>aihua Deng</last_name>
      <phone>13307096301</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dalian Tuberculosis Hospital</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>110000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing Ji</last_name>
      <phone>13009482267</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qingdao Chest Hospital</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yufeng Liu</last_name>
    </contact>
    <contact_backup>
      <phone>13863985511</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Taiyuan Fourth People's Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>quanhong Wang</last_name>
      <phone>13934242762</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xian Chest Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>liyun Dang</last_name>
      <phone>18091888085</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 20, 2017</study_first_submitted>
  <study_first_submitted_qc>February 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>February 20, 2021</last_update_submitted>
  <last_update_submitted_qc>February 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chest Hospital</investigator_affiliation>
    <investigator_full_name>Chu naihu</investigator_full_name>
    <investigator_title>Director,TB Department</investigator_title>
  </responsible_party>
  <keyword>pulmonary tuberculosis</keyword>
  <keyword>interleukin-2</keyword>
  <keyword>clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

